The Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. National Institute of Allergy and Infectious Diseases said in a statement.
AstraZeneca said it will seek clearance in the United States “in the coming weeks,” putting it on track to the country's fourth COVID vaccine to receive emergency use authorization and joining those from Pfizer, Moderna and Johnson & Johnson already in use.
